Alnylam Pharmaceuticals (ALNY) Amortization of Deferred Charges (2019 - 2024)

Alnylam Pharmaceuticals has reported Amortization of Deferred Charges for 6 years, with the latest figure at $13.1 million in Q3 2024.

• For the quarter ending Q3 2024, Amortization of Deferred Charges rose 27.95% year-over-year to $13.1 million; the trailing twelve-month figure through Sep 2024 stood at $45.2 million (up 4.98% YoY), and the FY2023 full-year result was $43.0 million, up 4.61% from the prior year.
• Amortization of Deferred Charges for Q3 2024 stood at $13.1 million, up from $9.7 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $13.1 million in Q3 2024, with the low at $9.4 million in Q1 2020.
• Historically, Amortization of Deferred Charges has averaged $10.6 million across 5 years, with a median of $10.3 million in 2023.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges fell 12.1% — and 2024, when it increased 27.95%.
• Alnylam Pharmaceuticals' Amortization of Deferred Charges stood at $10.5 million in 2020, then dropped by 3.98% to $10.1 million in 2021, then gained by 4.94% to $10.6 million in 2022, then fell by 0.78% to $10.5 million in 2023, then rose by 24.45% to $13.1 million in 2024.
• The last three Amortization of Deferred Charges figures came in at $13.1 million (Q3 2024), $9.7 million (Q2 2024), and $12.0 million (Q1 2024), per Business Quant data.